Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Exp Immunol ; 210(2): 91-103, 2022 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-36208448

RESUMEN

A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig®) confers acceptable efficacy, safety, and tolerability over a follow-up of up to 238 weeks (>4 years). Seventy-five patients received 4462 infusions during up to 70 weeks of follow-up in the main study and 27 patients received 2777 infusions during up to 168 weeks of follow-up in the extension. In the main study, there were no serious bacterial infections (SBIs), and the annual rate of other infections was 3.3 (95% CI 2.4, 4.5). One SBI was recorded in the extension, for an SBI rate of 0.02 (upper 99% CI 0.19). The annual rate of all infections over the duration of the extension study was 2.2 (95% CI 1.2, 3.9). Only 15.0% (1085) of 7239 infusions were associated with infusion site reactions (ISRs), leaving 85.0% (6153) of infusions without reactions. The majority of ISRs were mild and transient. ISR incidence decreased over time, from 36.9% to 16% during the main study and from 9% to 2.3% during the extension. The incidence of related systemic adverse events was 14.7% in the main study and 7.4% in the extension. In conclusion, this prospective, long-term study with cutaquig showed maintained efficacy and low rates of local and systemic adverse reactions in PID patients over up to 238 weeks of follow-up.


Asunto(s)
Infecciones Bacterianas , Síndromes de Inmunodeficiencia , Humanos , Estudios Prospectivos , Infusiones Subcutáneas , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Inmunoglobulina G/uso terapéutico , Resultado del Tratamiento , Inmunoglobulinas Intravenosas/uso terapéutico
2.
PLoS One ; 19(2): e0297439, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38306349

RESUMEN

The impacts of the Anthropocene on climate and biodiversity pose societal and ecological problems that may only be solved by ecosystem restoration. Local to regional actions are required, which need to consider the prevailing present and future conditions of a certain landscape extent. Modeling approaches can be of help to support management efforts and to provide advice to policy making. We present stage one of the LaForeT-PLUC-BE model (Landscape Forestry in the Tropics-PCRaster Land Use Change-Biogeographic & Economic model; in short: LPB) and its thematic expansion module RAP (Restoration Areas Potentials). LPB-RAP is a high-resolution pixel-based scenario tool that relies on a range of explicit land use types (LUTs) to describe various forest types and the environment. It simulates and analyzes future landscape configurations under consideration of climate, population and land use change long-term. Simulated Land Use Land Cover Change (LULCC) builds on dynamic, probabilistic modeling incorporating climatic and anthropogenic determinants as well as restriction parameters to depict a sub-national regional smallholder-dominated forest landscape. The model delivers results for contrasting scenario settings by simulating without and with potential Forest and Landscape Restoration (FLR) measures. FLR potentials are depicted by up to five RAP-LUTs. The model builds on user-defined scenario inputs, such as the Shared Socioeconomic Pathways (SSP) and Representative Concentration Pathways (RCP). Model application is here exemplified for the SSP2-RCP4.5 scenario in the time frame 2018-2100 on the hectare scale in annual resolution using Esmeraldas province, Ecuador, as a case study area. The LPB-RAP model is a novel, heuristic Spatial Decision Support System (SDSS) tool for smallholder-dominated forest landscapes, supporting near-time top-down planning measures with long-term bottom-up modeling. Its application should be followed up by FLR on-site investigations and stakeholder participation across all involved scales.


Asunto(s)
Conservación de los Recursos Naturales , Ecosistema , Conservación de los Recursos Naturales/métodos , Bosques , Biodiversidad , Agricultura Forestal/métodos
3.
PLoS One ; 17(7): e0271066, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35816490

RESUMEN

As ACE2 is the critical SARS-CoV-2 receptor, we hypothesized that aerosol administration of clinical grade soluble human recombinant ACE2 (APN01) will neutralize SARS-CoV-2 in the airways, limit spread of infection in the lung, and mitigate lung damage caused by deregulated signaling in the renin-angiotensin (RAS) and Kinin pathways. Here, after demonstrating in vitro neutralization of SARS-CoV-2 by APN01, and after obtaining preliminary evidence of its tolerability and preventive efficacy in a mouse model, we pursued development of an aerosol formulation. As a prerequisite to a clinical trial, we evaluated both virus binding activity and enzymatic activity for cleavage of Ang II following aerosolization. We report successful aerosolization for APN01, retaining viral binding as well as catalytic RAS activity. Dose range-finding and IND-enabling repeat-dose aerosol toxicology testing were conducted in dogs. Twice daily aerosol administration for two weeks at the maximum feasible concentration revealed no notable toxicities. Based on these results, a Phase I clinical trial in healthy volunteers has now been initiated (NCT05065645), with subsequent Phase II testing planned for individuals with SARS-CoV-2 infection.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Aerosoles , Enzima Convertidora de Angiotensina 2 , Angiotensinas , Animales , Ensayos Clínicos Fase I como Asunto , Perros , Humanos , Ratones , Nebulizadores y Vaporizadores , Peptidil-Dipeptidasa A/metabolismo , Renina/metabolismo , Sistema Renina-Angiotensina , SARS-CoV-2
4.
bioRxiv ; 2021 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-34545364

RESUMEN

To develop a universal strategy to block SARS-CoV-2 cellular entry and infection represents a central aim for effective COVID-19 therapy. The growing impact of emerging variants of concern increases the urgency for development of effective interventions. Since ACE2 is the critical SARS-CoV-2 receptor and all tested variants bind to ACE2, some even at much increased affinity (see accompanying paper), we hypothesized that aerosol administration of clinical grade soluble human recombinant ACE2 (APN01) will neutralize SARS-CoV-2 in the airways, limit spread of infection in the lung and mitigate lung damage caused by deregulated signaling in the renin-angiotensin (RAS) and Kinin pathways. Here we show that intranasal administration of APN01 in a mouse model of SARS-CoV-2 infection dramatically reduced weight loss and prevented animal death. As a prerequisite to a clinical trial, we evaluated both virus binding activity and enzymatic activity for cleavage of Ang II following aerosolization. We report successful aerosolization for APN01, retaining viral binding as well as catalytic RAS activity. Dose range-finding and IND-enabling repeat-dose aerosol toxicology testing were conducted in dogs. Twice daily aerosol administration for two weeks at the maximum feasible concentration revealed no notable toxicities. Based on these results, a Phase I clinical trial in healthy volunteers can now be initiated, with subsequent Phase II testing in individuals with SARS-CoV-2 infection. This strategy could be used to develop a viable and rapidly actionable therapy to prevent and treat COVID-19, against all current and future SARS-CoV-2 variants.

5.
Drug Dev Ind Pharm ; 35(8): 997-1002, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19365777

RESUMEN

BACKGROUND: Chitosan-EDTA is an interesting matrix for dermal delivery; however, the adhesiveness is too small. Therefore, the purpose of this study was to investigate chitosan-glycolic acid as possible dermal matrix for progesterone in comparison to chitosan-EDTA and carrageenan. METHOD: After preparation of the chitosan-glycolic acid salt and characterization by NMR and FTIR, tensile studies using porcine skin and rheology measurements as well as standard diffusion experiments using dermatomed porcine skin were performed. RESULTS: Results showed an improved skin adhesiveness of chitosan-glycolic acid and increased viscosity. Skin diffusion studies indicated the highest cumulative permeation of progesterone after 48 hours from chitosan-glycolic acid followed by carrageenan and chitosan-EDTA. A possible explanation might be a longer residence time on skin caused by the higher adhesiveness and with it higher progesterone skin permeation. CONCLUSION: Chitosan-glycolic acid can be recommended as a suitable polymer for hydrogels and an adhesive matrix for a transdermal application of progesterone exhibiting excellent skin adhesiveness and permeation properties.


Asunto(s)
Quitosano/química , Portadores de Fármacos/química , Glicolatos/química , Progesterona/farmacocinética , Adhesividad , Administración Cutánea , Animales , Carragenina/química , Difusión , Sistemas de Liberación de Medicamentos , Ácido Edético/química , Permeabilidad , Progesterona/administración & dosificación , Absorción Cutánea , Porcinos , Factores de Tiempo
6.
Clin Cosmet Investig Dermatol ; 12: 857-864, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31819583

RESUMEN

PURPOSE: Nasolabial folds (NLFs) are one of the most noticeable signs of facial aging. NLFs negatively affect self-confidence and social acceptance often leading to a person's desire to improve their appearance using dermal fillers. The hyaluronic acid injectable gel implant Princess® FILLER Lidocaine (PFL) is a minimally invasive easy to administer the product. In this investigation, we assessed the safety and efficacy of PFL to correct moderate to severe NLFs over a 36-week period. METHODS: Adult women and men with moderate to severe NLFs received one injection of PFL to both NLFs. After 2 weeks, a touch-up treatment could be performed, if deemed necessary by the investigator. The change in NLF severity was assessed using the Nasolabial Fold Severity Rating Scale (NFL-SRS) developed by Croma-Pharma and the Global Aesthetic Improvement Scale (GAIS). RESULTS: Out of 60 analyzed subjects, 59 (98.3%) had improved their NLF severity by at least 1 grade on the NFL-SRS at week 4, 58 subjects (96.7%) at weeks 24 and 36. All subjects showed aesthetic improvement (GAIS), at weeks 4 and 24. The investigator judged the aesthetics as very much improved (score of 1) in 45 (75.0%) at week 4, 48 (80.0%) at week 24, and in 39 of 60 subjects, respectively (65.0%) at week 36. Thirty-six weeks post-initial treatment, 56 of 60 subjects (93.3%) were very satisfied or satisfied with the treatment. Adverse device effects (ADEs) were mild or moderate and resolved at latest 25 days post-onset. The most commonly reported ADEs were injection site hematoma and injection site pain. CONCLUSION: PFL was safe and effective in reducing the severity of NLFs. Most subjects were (very) satisfied with the treatment outcome throughout a 36 weeks investigation period.

7.
Eur J Pharm Biopharm ; 66(1): 120-6, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17055710

RESUMEN

The purpose of the present study was to investigate the influence of different drugs exhibiting different solubility on the viscoelastic properties and on the skin diffusion profile of a ringing gel. In a preliminary rheology study with the placebo gel predominating elastic properties were confirmed and a temperature influence was indicated. Fluconazole, fludrocortisone-acetate, flumethasone-pivalate, flutamide and flufenamic-acid each 1% (w/w) were incorporated into the preparation and oscillatory measurements were performed at temperatures of 25, 28, 32 and 37 degrees C. In all drug containing formulations a high elastic G' value predominated the viscous G'' value. The highest G' value could be obtained with the incorporated flumethasone-pivalate. Additionally in almost all cases the G' values decreased with increasing temperature compared to the placebo gel. Additionally in vitro standard diffusion experiments using Franz-type cells and porcine skin were performed. Following rank order of the cumulative drug release after 48 h was obtained: fluconazole>flufenamic-acid>flumethasone-pivalate>flutamide>fludrocortisone-acetate. Furthermore an excellent chemical stability of all incorporated drugs was confirmed over 10 weeks.


Asunto(s)
Compuestos de Flúor/química , Preparaciones Farmacéuticas/química , Absorción Cutánea , Piel/metabolismo , Animales , Difusión , Estabilidad de Medicamentos , Fluconazol/química , Fluconazol/farmacocinética , Fludrocortisona/química , Fludrocortisona/farmacocinética , Ácido Flufenámico/química , Ácido Flufenámico/farmacocinética , Flumetasona/análogos & derivados , Flumetasona/química , Flumetasona/farmacocinética , Flutamida/química , Flutamida/farmacocinética , Geles , Interacciones Hidrofóbicas e Hidrofílicas , Técnicas In Vitro , Aceites/química , Parafina/química , Permeabilidad , Preparaciones Farmacéuticas/metabolismo , Temperatura Cutánea , Solubilidad , Tensoactivos/química , Porcinos , Viscosidad , Agua/química
8.
J Ocul Pharmacol Ther ; 33(5): 375-382, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28441068

RESUMEN

PURPOSE: This study was designed to evaluate the effect of chitosan-N-acetylcysteine (C-NAC) eye drops on tear film thickness (TFT) in patients with dry eye syndrome (DES). METHODS: This was a controlled, randomized, double-blind clinical investigation with patients assigned to 2 cohorts. In Cohort I, 21 patients were randomized to receive 1 instillation of C-NAC eye drops in 1 eye and placebo (normal saline solution) in the contralateral eye. In Cohort II, 17 patients were randomized to receive C-NAC eye drops once (QD) or twice (BID) daily for 5 days. TFT was assessed with a custom-built ultrahigh-resolution optical coherence tomography system. RESULTS: In Cohort I, mean TFT increased from 3.9 ± 0.5 µm predose to 4.8 ± 1.1 µm 10 min postdose after treatment with C-NAC. The increase was significantly different from placebo over time (P < 0.0001) and remained stable until 24 h postdose. In Cohort II, TFT increased with QD and BID instillation, with no significant difference between regimens. In both groups, Ocular Surface Disease Index scores improved, fewer patients presented with corneal damage, and symptoms of ocular discomfort/conjunctival redness were reduced. CONCLUSIONS: A single instillation of C-NAC significantly increased mean TFT in patients with DES as early as 10 min after instillation and lasted for 24 h. The magnitude of the increase in TFT following a single instillation was comparable with that after instillation twice daily over 5 days. Corneal damage improved in >60% of patients. C-NAC could be a viable treatment option for DES.


Asunto(s)
Acetilcisteína/efectos adversos , Acetilcisteína/uso terapéutico , Quitosano/análogos & derivados , Síndromes de Ojo Seco/tratamiento farmacológico , Acetilcisteína/administración & dosificación , Adulto , Quitosano/administración & dosificación , Quitosano/efectos adversos , Quitosano/uso terapéutico , Estudios de Cohortes , Método Doble Ciego , Femenino , Humanos , Masculino , Lágrimas/química , Lágrimas/metabolismo , Tomografía de Coherencia Óptica
9.
Cartilage ; 7(3): 265-73, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27375842

RESUMEN

PURPOSE: An important feature of biomaterials used in cartilage regeneration is their influence on the establishment and stabilization of a chondrocytic phenotype of embedded cells. The purpose of this study was to examine the effects of a porous 3-dimensional scaffold made of cross-linked hyaluronic acid on the expression and synthesis performance of human articular chondrocytes. MATERIALS AND METHODS: Osteoarthritic chondrocytes from 5 patients with a mean age of 74 years were passaged twice and cultured within the cross-linked hyaluronic acid scaffolds for 2 weeks. Analyses were performed at 3 different time points. For estimation of cell content within the scaffold, DNA-content (CyQuant cell proliferation assay) was determined. The expression of chondrocyte-specific genes by embedded cells as well as the total amount of sulfated glycosaminoglycans produced during the culture period was analyzed in order to characterize the synthesis performance and differentiation status of the cells. RESULTS: Cells showed a homogenous distribution within the scaffold. DNA quantification revealed a reduction of the cell number. This might be attributed to loss of cells from the scaffold during media exchange connected with a stop in cell proliferation. Indeed, the expression of cartilage-specific genes and the production of sulfated glycosaminoglycans were increased and the differentiation index was clearly improved. CONCLUSIONS: These results suggest that the attachment of osteoarthritic P2 chondrocytes to the investigated material enhanced the chondrogenic phenotype as well as promoted the retention.

10.
Biomed Res Int ; 2015: 195328, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25821787

RESUMEN

The dermal filler Princess VOLUME is a highly cross-linked, viscoelastic hyaluronic acid injectable gel implant used for aesthetic treatment. To evaluate the efficacy and safety of Princess VOLUME in the treatment of nasolabial folds, an open-label uncontrolled, multicenter study was conducted. Forty-eight subjects were recruited who had moderate to deep wrinkles, according to the Modified Fitzpatrick Wrinkle Scale (MFWS). Subjects received Princess VOLUME in both nasolabial folds at Day 0. Nasolabial fold severity was evaluated at 30, 90, 180, and 270 days after treatment, using the MFWS and the Global Aesthetic Improvement Scale (GAIS). Adverse events and treatment site reactions were recorded. Among the 48 subjects, 93.8% were female with a median age of 52 years. There were significant improvements (P < 0.0001) in the MFWS scores at 30, 180, and 270 days after treatment compared with those at baseline, with a mean decrease of 1.484 (±0.408), 1.309 (±0.373), and 1.223 (±0.401), respectively; hence the primary endpoint was achieved and clinical efficacy demonstrated. Princess VOLUME was well tolerated, and most adverse events were injection site reactions of mild to moderate severity. Subject satisfaction (97.9%), subject recommendation of the treatment (93.6%), and investigators GAIS scores (97.9% improvement) were high.


Asunto(s)
Técnicas Cosméticas , Rellenos Dérmicos/efectos adversos , Rellenos Dérmicos/uso terapéutico , Surco Nasolabial/anatomía & histología , Envejecimiento de la Piel/efectos de los fármacos , Adulto , Anciano , Austria , Femenino , Humanos , Persona de Mediana Edad , Satisfacción del Paciente , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA